ライフサイエンスコーパス: vaccine efficacy

1 is reduced by a factor that is equal to the vaccine efficacy).

2 me regimen, and a delayed vaccine boost upon vaccine efficacy.

3 host-related differences in influenza virus vaccine efficacy.

4 er of vaccines by providing an indication of vaccine efficacy.

5 from severe dengue virus (DENV) disease and vaccine efficacy.

6 e Th1 and Th17 cell lineages may improve BCG vaccine efficacy.

7 ortant roles as modifiers of influenza virus vaccine efficacy.

8 utting-edge analysis of innate biomarkers of vaccine efficacy.

9 ine trial associated antibody responses with vaccine efficacy.

10 s from which they were derived, compromising vaccine efficacy.

11 accination are significantly associated with vaccine efficacy.

12 ich may be high in elderly subjects, impairs vaccine efficacy.

13 tudies of cervical precancer risk and of HPV vaccine efficacy.

14 ugh PIR-B-NOTCH signaling and enhances tumor vaccine efficacy.

15 B/subtype E (B/E) proteins demonstrated 31% vaccine efficacy.

16 ver, there are limited data validating their vaccine efficacy.

17 ine-induced CD4(+) cells in cross-protective vaccine efficacy.

18 regions of the glycoprotein does not enhance vaccine efficacy.

19 gion of AMA1 associated with strain-specific vaccine efficacy.

20 ion of neuraminidase (NA) to influenza virus vaccine efficacy.

21 learance compared to controls, demonstrating vaccine efficacy.

22 sess the impact of the immunization route on vaccine efficacy.

23 the quality of antibody responses to improve vaccine efficacy.

24 , robust T cell responses could enhance ZIKV vaccine efficacy.

25 lications of these results for understanding vaccine efficacy.

26 nerated by the PCS vaccine was predictive of vaccine efficacy.

27 N) junction or deletion of PIV5 SH increased vaccine efficacy.

28 the microbiota and immunity is critical for vaccine efficacy.

29 novel approach in determining mechanisms of vaccine efficacy.

30 nd efficient assessment of the durability of vaccine efficacy.

31 nfection following immunization and augments vaccine efficacy.

32 e framework for understanding and evaluating vaccine efficacy.

33 l centres (GCs) promote humoral immunity and vaccine efficacy.

34 but similar anti-infectivity may not improve vaccine efficacy.

35 onses, and LATS1/2 deficiency enhances tumor vaccine efficacy.

36 y (January-June 2015), vaccine coverage, and vaccine efficacy.

37 ity, potency of therapeutic intervention and vaccine efficacy.

38 didate to ongoing phase 2/3 trials to assess vaccine efficacy.

39 ovide insights to overcome bottlenecks in TB vaccine efficacy.

40 ection, historical vaccination coverage, and vaccine efficacy.

41 Tcm/Tem cell ratio is essential for optimal vaccine efficacy.

42 rks in influencing antimalarial immunity and vaccine efficacy.

43 tailored adjuvants could potentially improve vaccine efficacy.

44 oader impact of immunoregulatory networks on vaccine efficacy.

45 inistering Ag at this checkpoint may improve vaccine efficacy.

46 sting that 2 and 3 doses may have comparable vaccine efficacy.

47 l expansion, which in turn provides improved vaccine efficacy.

48 Tobacco smoke exposure also reduces vaccine efficacy.

49 t to the general definition of correlates of vaccine efficacy.

50 ntifying ways by which to improve upon RV144 vaccine efficacy.

51 tion and improve vaccine design and increase vaccine efficacy.

52 tions introduced by egg adaptation decreased vaccine efficacy.

53 on of correlates of protection necessary for vaccine efficacy.

54 HIV-1 clinical trial to date to demonstrate vaccine efficacy.

55 CS-specific T cell responses correlated with vaccine efficacy.

56 reagents to monitor disease progression and vaccine efficacy.

57 it vaccines contain epitopes unfavorable for vaccine efficacy.

58 nd the circulating strains, which diminishes vaccine efficacy.

59 ponse that would yield pronounced protective vaccine efficacy.

60 h constitutive IL-10 level adversely affects vaccine efficacy.

61 ng is important to study natural history and vaccine efficacy.

62 for immuno-monitoring and could help predict vaccines efficacy.

63 (13%) of 1633 of IPV recipients (total IIV3 vaccine efficacy 25.6% [95% CI 6.8-40.6]; p=0.010).

64 vaccine group and 2.4% in the placebo group (vaccine efficacy, 39.4%; 97.52% CI, -1.0 to 63.7; 95% CI

65 (10%) of 1814 IPV recipients had influenza (vaccine efficacy 41.0% [24.1-54.1]; p<0.0001).

66 piratory tract infection were 2.1% and 3.7% (vaccine efficacy, 44.4%; 95% CI, 19.6 to 61.5).

67 on with severe hypoxemia were 0.5% and 1.0% (vaccine efficacy, 48.3%; 95% CI, -8.2 to 75.3), and the

68 and LcrV (5 mug each) dramatically improved vaccine efficacy (70-80%).

69 1 (5%) of 1786 IPV recipients had influenza (vaccine efficacy 74.2% [57.8-84.3]; p<0.0001).

70 ) and 4 of 33 (12.1%) vaccinees at 3 months (vaccine efficacy, 79.5%; P < .0001).

71 accine (428 cases per 100,000 person-years) (vaccine efficacy, 81.6%; 95% confidence interval, 58.8 t

72 ut only 2 of 35 (5.7%) vaccinees at 10 days (vaccine efficacy, 90.3%; P < .0001) and 4 of 33 (12.1%)

73 Specifically, in clinical trials of vaccine efficacy, a readout of protection against TB dis

74 Overall vaccine efficacy across both groups was 70.4% (95.8% CI

75 e according-to-protocol cohort for efficacy, vaccine efficacy against 6-month persistent infection or

76 The primary endpoint was vaccine efficacy against 6-month persistent infection or

77 Vaccine efficacy against all varicella was 95.4% (95% CI

78 The observed vaccine efficacy against asymptomatic dengue virus infec

79 In the total vaccinated cohort, vaccine efficacy against CIN1+ irrespective of HPV was s

80 e need for continued monitoring of rotavirus vaccine efficacy against emerging rotavirus genotypes.IM

81 Estimated vaccine efficacy against herpes zoster in patients with

82 VZV vaccine was well tolerated and estimated vaccine efficacy against herpes zoster was 16.8% (95% CI

83 Cumulative vaccine efficacy against HPV 16/18-associated CIN2+ over

84 Vaccine efficacy against HPV 16/18-related cytological a

85 l viral antigens may not necessarily improve vaccine efficacy against immunodeficiency virus infectio

86 At year 11, vaccine efficacy against incident HPV 16/18-associated C

87 In year 1, total vaccine efficacy against influenza A(H1N1)pdm09 was 14.5

88 In year 2, total vaccine efficacy against influenza A(H3N2) was 64.5% (48

89 Total vaccine efficacy against influenza B was 32.5% (11.3-48.

90 The study was not powered to evaluate vaccine efficacy against influenza infection.

91 We assessed two coprimary objectives: vaccine efficacy against laboratory-confirmed influenza

92 for MMRV and 67.2% (62.3-71.5) for MMR + V; vaccine efficacy against moderate or severe varicella wa

93 her than an M1, response may further improve vaccine efficacy against ocular HSV-1 replication and la

94 are increasing in incidence among males, and vaccine efficacy against oral HPV infections in men has

95 aches to estimate VES, and we also estimated vaccine efficacy against progression to symptoms (VEP).

96 of protein per dose) to compare the relative vaccine efficacy against reverse-transcriptase polymeras

97 Vaccine efficacy against susceptibility to infection (VE

98 Testing vaccine efficacy against the highly lethal Ebola virus (

99 90 days of life, and the primary analysis of vaccine efficacy against the primary end point was perfo

100 Many studies have documented lower vaccine efficacy among children in low-income countries,

101 ards regression model were used to calculate vaccine efficacy and 95% CI.

102 ant in viral spread and its implications for vaccine efficacy and antibody therapy.

103 as important factors that may reduce overall vaccine efficacy and cause vaccine failure.

104 y viruses (SHIVs) have been utilized to test vaccine efficacy and characterize mechanisms of viral tr

105 However, vaccine efficacy and direct effectiveness estimates have

106 Understanding vaccine efficacy and duration of immunity, and how these

107 ion strategies under a range of scenarios of vaccine efficacy and duration of protection, and emergen

108 Focusing on studies of vaccine efficacy and effectiveness in emergencies, we hi

109 We discuss factors that contribute to vaccine efficacy and how these parameters may potentiall

110 mpact of a TLR5 agonist (flagellin; FliC) on vaccine efficacy and immunogenicity was also examined.

111 Both direct vaccine efficacy and indirect herd protection contribute

112 f delay in vaccine introduction with limited vaccine efficacy and limited supplies are not unlikely i

113 To provide a full picture of vaccine efficacy and make efficient use of available dat

114 he improvement is more pronounced for higher vaccine efficacy and moderate flu season intensity.

115 t on cost-effectiveness than improvements to vaccine efficacy and moderate increases in coverage.

116 Vaccine efficacy and pathogenesis studies for EV71 have

117 IMs) represent a valuable tool for assessing vaccine efficacy and potentially accelerating licensure.

118 is valuable for assessing candidate Shigella vaccine efficacy and potentially accelerating regulatory

119 ted by BPZE1 may hold prospects of improving vaccine efficacy and protection against B. pertussis tra

120 5-NA, could improve seasonal influenza virus vaccine efficacy and provide protection against emerging

121 In order to increase the vaccine efficacy and reduce the antigen dose, there is a

122 bisco((R))-100 and CoVaccineHT(TM), enhanced vaccine efficacy and sterile protection following malari

123 represent an important tool for analysis of vaccine efficacy and the immune mechanisms associated wi

124 lion childhood deaths annually; however, low vaccine efficacy and the resulting need for booster dose

125 l for vaccine development, interpretation of vaccine efficacy and the treatment for autoimmune diseas

126 okine production that can be used to promote vaccine efficacy and the treatment of infections and mal

127 Sensitivity analysis for vaccine compliance, vaccine efficacy and vaccine start date was also conduct

128 e development of novel strategies to improve vaccine efficacy and/or implementation of enhanced treat

129 ty analyses by varying vaccination coverage, vaccine efficacy, and duration of protection.

130 rt of a vaccine design dramatically improved vaccine efficacy, and this finding underlines the import

131 fluorescent) was compared in vitro and their vaccine efficacy (antigen-specific antibody responses an

132 ulate levels of OmpA and therefore potential vaccine efficacy are unknown.

133 New strategies to address the gap in oral vaccine efficacy are urgently required.

134 The vaccine efficacy, as assessed by negative binomial regre

135 The vaccine efficacy at month 36 was 49.7% (90% confidence i

136 called MADE (Measuring Adaptive Distance and vaccine Efficacy based on allelic barcodes) to measure t

137 d Linear Array in SUCCEED or in estimates of vaccine efficacy between TypeSeq and SPF10-LiPA in CVT.

138 increases in pathogen exposure dose decrease vaccine efficacy, but this effect is modified by heterog

139 We assumed constant vaccine efficacy by age, but varied coverage and degree

140 s age distributions, vaccine timeliness, and vaccine efficacy by duration of follow-up), new rotaviru

141 Mucosal immunization may enhance HIV vaccine efficacy by eliciting protective responses at po

142 tions for Tfr cell biology and for improving vaccine efficacy by formulating vaccines that modify the

143 We aimed to enhance vaccine efficacy by generating a more immunogenic CSP-ba

144 re was no evidence of effect modification of vaccine efficacy by precipitation (89% power).

145 We calculated vaccine efficacy by year and cumulatively.

146 Vaccine efficacy can be increased by arraying immunogens

147 Vaccine efficacy correlated with serum neutralizing anti

148 antibody-enhanced infection and suggest that vaccine efficacy could be improved by exploiting cross-r

149 Furthermore, the longevity of vaccine efficacy critically depends on the magnitude of

150 mode of vaccine action is highly polarized, vaccine efficacy decreases more slowly with exposure dos

151 ring self-limited infection that may help in vaccine efficacy definition, and in identifying possible

152 nder groups versus the middle group and when vaccine efficacy differed the most between the high- and

153 The significant vaccine efficacy documented 10 days and 3 months after 1

154 ate the guinea pig as a model for evaluating vaccine efficacy during pregnancy, nonpregnant guinea pi

155 transmissibility and 5-fold fractional-dose vaccine efficacy for two vaccination scenarios, ie, rand

156 Vaccine efficacy for vaccinated girls, HE for unvaccinat

157 Similar vaccine efficacy (generally 90 to 100%) was observed acr

158 nnual strain composition, the variability in vaccine efficacy hampers our ability to make long-term p

159 However, to date, limited vaccine efficacy has been reported and none have been li

160 The impact of the capsule on vaccine efficacy has not been explored.

161 rtance of innate immune contributions toward vaccine efficacy has only recently been recognized.

162 The estimated vaccine efficacy here was 100% (95% CI 79.3-100.0, p=0.0

163 ge with pathogenic SIVmac251, resulting in a vaccine efficacy (i.e., risk reduction per exposure) of

164 to develop a robust system for testing HIV-1 vaccine efficacy.IMPORTANCE Advances in the development

165 4 trial was held contributed to the observed vaccine efficacy.IMPORTANCE HIV-1-infected cells present

166 y has significant implications for improving vaccine efficacies in young children, the elderly, and i

167 eukocytes (PBLs) represent a means to bridge vaccine efficacy in animal models to that in humans.

168 n dose as mechanisms responsible for reduced vaccine efficacy in high transmission settings.

169 Vaccine efficacy in HIV-uninfected women was similar for

170 es to V2 are also important hallmarks of HIV-vaccine efficacy in humans will require further studies.

171 epartum (intention-to-treat population), and vaccine efficacy in infants born to women immunised at l

172 hanisms, providing the rationales to improve vaccine efficacy in infants, the elderly, immunocompromi

173 However, tuberculosis vaccine efficacy in mice is critically dependent on the

174 e migratory pattern of lymphocytes, and thus vaccine efficacy in mucosal tissues.

175 h may reveal spatio-temporal determinants of vaccine efficacy in preclinical and translational studie

176 The primary end point was overall vaccine efficacy in preventing virologically confirmed d

177 tious challenge strains are needed to assess vaccine efficacy in the controlled human infection model

178 ed factors contributing to reduced influenza vaccine efficacy in the elderly and uncovered a dramatic

179 The overall vaccine efficacy in the safety population was 80.9% (95%

180 ntrol groups in two phase 3 trials of dengue vaccine efficacy included two large regional cohorts tha

181 The analytical cohort for vaccine efficacy included women who were HPV 16/18 DNA-n

182 inst lethal Y. enterocolitica infection, and vaccine efficacy increased to 90-100% when they received

183 Strategies employed to improve vaccine efficacy involve using structure-based design an

184 Vaccine efficacy is associated with the ability of CMV t

185 Vaccine efficacy is attributed to long-term protective i

186 nd research tools to determine infection and vaccine efficacy is critically needed.

187 When the vaccine efficacy is investigated in aged-ferrets that re

188 Rotavirus vaccine efficacy is lower and wanes more rapidly in high

189 Rotavirus vaccine efficacy is lower in low-income countries than i

190 age in girls and boys is reached and if high vaccine efficacy is maintained over time.

191 s for TB, understanding the effect of NTM on vaccine efficacy may be a critical determinant of succes

192 ce from experimental infection suggests that vaccine efficacy may be affected by parasite-induced imm

193 cumulating evidence suggests that diminished vaccine efficacy may be related to repeated vaccination.

194 capacity to evade host immune responses, HIV vaccine efficacy may benefit from the induction of both

195 influenza vaccination, raising concerns that vaccine efficacy might wane.

196 The 10-years vaccine efficacy observed, suggests that a two-dose sche

197 f 35 participants in the Vi-PS group to give vaccine efficacies of 54.6% (95% CI 26.8-71.8) for Vi-TT

198 esulted in a reduction of attack rates, with vaccine efficacies of 66.7% (P = 0.02), 77.7% (P = 0.006

199 l model to study transmission, diseases, and vaccine efficacies of respiratory viruses because of the

200 nd 105 (18%) of placebo recipients, giving a vaccine efficacy of 0.0% (95% CI -26.4 to 20.9).

201 rojected across a range of uncertainty about vaccine efficacy of 0.268 (95% CI: 0.210-0.329).

202 converted between months 13 and 25, giving a vaccine efficacy of 33.5% (95% confidence interval [CI],

203 nts (6.0 [95% CI, 4.3-8.5]; 33 cases) with a vaccine efficacy of 43.1% (P = .050).

204 ce rate ratio, 0.43 [95% CI, .19-.93]) for a vaccine efficacy of 57.5% (P = .032).

205 s per 100 person-years, respectively), for a vaccine efficacy of 66.7% (95% confidence interval [CI],

206 intention-to-treat analyses, which showed a vaccine efficacy of 69.1% (95% CI, 55.0 to 78.7).

207 ry endpoint assessment timeframe, an overall vaccine efficacy of 73.3% (95% CI 66.5 to 78.8) was obse

208 ion that was seronegative at baseline showed vaccine efficacy of 74.9% (95% CI, 57.0 to 85.4; 20 case

209 Under certain assumptions, at an overall vaccine efficacy of 75%, 50 Ebola endpoints in the vacci

210 rimary endpoint was achieved with an overall vaccine efficacy of 80.2% (95% CI 73.3 to 85.3; 61 cases

211 -Pasteur formulations) yielded an overall aP vaccine efficacy of 84% (95% confidence interval [CI], 8

212 At an overall vaccine efficacy of 90%, 20 Ebola endpoints gave good po

213 clades of HPAI A(H5) viruses in Vietnam, the vaccine efficacy of bivalent poultry vaccine formulation

214 Vaccine efficacy of LAIV for vaccine-matched strains was

215 The utility of serologic testing to evaluate vaccine efficacy of seasonal inactivated influenza vacci

216 We assessed the 10-year vaccine efficacy of two doses of a combined measles-mump

217 led human malaria infection (CHMI) to assess vaccine efficacy offer a unique opportunity to study the

218 d that vaccine duration had more impact than vaccine efficacy on modelled EBV and IM prevalence.

219 mphoid sites, which could be used to enhance vaccine efficacy or adoptive cell therapy treatments tha

220 f published studies that evaluated pertussis vaccine efficacy or effectiveness within 3 years after c

221 s of interventions designed to increase oral vaccine efficacy or immunogenicity.

222 if these immune responses are predictors of vaccine efficacy or markers of natural resistance to HIV

223 umoral and cellular immune responses, and on vaccine efficacy or vaccine effectiveness after two-dose

224 Given waning vaccine efficacy over time, this secondary analysis demo

225 nderstanding antigenic evolution and informs vaccine efficacy predictions based on the genetic sequen

226 Vaccine efficacy remained robust during the first 4 mont

227 e effect of this variant on viral spread and vaccine efficacy remains to be defined.

228 neutralization escape that could compromise vaccine efficacy, sera from spike-immunized mice, nonhum

229 Meta-analysis of 2 aP vaccine efficacy studies (assessing the 3-component Glax

230 limitations of using surrogate endpoints for vaccine efficacy studies of mid-adult women to guide pol

231 human hookworm model to accelerate drug and vaccine efficacy studies.

232 The RV 144 HIV vaccine efficacy study showed a reduction in HIV-1 infec

233 If constitutive IL-10 impairs vaccine efficacy, the effectiveness of viral vaccines mi

234 xpected value of resolving uncertainty about vaccine efficacy, time delay to immunity after vaccinati

235 Vaccine efficacy to eliminate colonisation could also be

236 udies on EV71 antiviral drug susceptibility, vaccine efficacy, transmissibility, and pathogenesis.

237 in a randomized controlled preventive HIV-1 vaccine efficacy trial can help elucidate mechanisms of

238 We analysed data from a reported vaccine efficacy trial of the tuberculosis vaccine MVA85

239 HVTN 505 is a preventative vaccine efficacy trial testing DNA followed by recombina

240 IV-1 acquisition in a phase IIb preventative vaccine efficacy trial, HVTN 505.

241 rrelate of decreased HIV-1 risk in the RV144 vaccine efficacy trial, suggesting that protection might

242 HIV Vaccine Trials Network (HVTN) 505 HIV-1 vaccine efficacy trial.

243 of the partially efficacious Thai RV144 HIV vaccine efficacy trial.

244 y B cells in RMs as observed in the HVTN 505 vaccine efficacy trial.

245 ulations in Uganda, during two Simulated HIV Vaccine Efficacy trials (SiVETs).

246 For example, many vaccine efficacy trials focus on measuring protection ag

247 humans and is not a suitable strain for HgbA vaccine efficacy trials in the model.

248 on regimens.IMPORTANCE The evaluation of HIV vaccine efficacy trials indicates that protection would

249 8 cross-reactivity in two preventative HIV-1 vaccine efficacy trials, the MRKAd5 and DNA/rAd5 studies

250 ction of preventive antibodies in future HIV vaccine efficacy trials.

251 orm selection of clinical end points for RSV vaccine efficacy trials.

252 ccine-induced CD8 T-cell responses in 2 past vaccine efficacy trials.

253 ses performed on four major preventive HIV-1 vaccine efficacy trials: (i) the HIV Vaccine Trial Netwo

254 Ongoing strategies to improve vaccine efficacy typically focus on providing broad-spec

255 enge model is suitable for the assessment of vaccine efficacy using endpoints that include bacteremia

256 seropositive infants, geometric mean titre, vaccine efficacy, vaccine effectiveness, antibody avidit

257 Vaccine efficacy varied by serotype, warranting continue

258 sion model to estimate the pooled cumulative vaccine efficacy (VE) and its waning with time for three

259 Rotavirus vaccine efficacy (VE) estimates in low-resource settings

260 ith a fractional third dose can produce high vaccine efficacy (VE) in adults challenged 3 weeks after

261 cine and placebo groups, respectively, for a vaccine efficacy (VE) of -7.1% (90% confidence interval

262 When vaccine efficacy (VE) of 5 doses of 2.7 x 105 PfSPZ of P

263 When vaccine efficacy (VE) of 5 doses of 2.7x105 PfSPZ of PfS

264 the effect of Y1 vaccination on Y2 relative vaccine efficacy (VE), immunogenicity (hemagglutination

265 onated eggs) have been implicated in reduced vaccine efficacy (VE), their respective contributions to

266 enabled virus genotype-specific estimates of vaccine efficacy (VE).

267 ssess high-risk HPV variant lineage-specific vaccine efficacy (VE).

268 Time-varying vaccine efficacy (VE[t]) was examined in healthy adult p

269 al of 26 of 30 subjects in the Fx017M group (vaccine efficacy [VE], 86.7% [95% confidence interval [C

270 Vaccine efficacy waned over time (P=0.006 for the intera

271 The hazard ratio for vaccine efficacy was 0.517 (95% CI 0.313-0.856) by time-

272 Vaccine efficacy was 100% (95% CI 68.9-100.0, p=0.0045),

273 /18-associated CIN3-specifically at year 11, vaccine efficacy was 100% (95% CI 78.8-100.0) and cumula

274 ntention-to-treat population, overall infant vaccine efficacy was 33.1% (95% CI 3.7-53.9); in the per

275 ime to first acquisition of vaginal GBS III, vaccine efficacy was 36% (95% confidence interval [CI],

276 I 3.7-53.9); in the per-protocol population, vaccine efficacy was 37.3% (7.6-57.8).

277 articipants who received two standard doses, vaccine efficacy was 62.1% (95% CI 41.0-75.7; 27 [0.6%]

278 Direct vaccine efficacy was 71%.

279 In the per-protocol analyses, vaccine efficacy was 80.2% (95% CI, 73.3 to 85.3; 61 cas

280 per 1000 person-years; 95% CI, 1.7 to 6.0); vaccine efficacy was 94.1% (95% CI, 89.3 to 96.8%; P<0.0

281 was 100% (95% CI 78.8-100.0) and cumulative vaccine efficacy was 94.9% (73.7-99.4).

282 The association between RAS activation and vaccine efficacy was also observed in an independent eff

283 Vaccine efficacy was assessed in a skin challenge and in

284 Vaccine efficacy was associated with alum-induced, but n

285 Vaccine efficacy was calculated as 1 - relative risk der

286 No statistically significant vaccine efficacy was found against the non-laboratory-co

287 parasites expressing both PfUIS3 and PfTRAP, vaccine efficacy was improved to 100% sterile protection

288 Vaccine efficacy was marginally higher in subjects aged

289 Protective vaccine efficacy was observed in 14 of 17 subjects (82.4

290 Also, vaccine efficacy was similar for PCR-CI (61.2%; 95% CI,

291 Although vaccine efficacy was similar when measured for PCR-CI or

292 Vaccine efficacy was sustained for up to 6 years.

293 Vaccine efficacy was tested against opioid-induced behav

294 t-second dose, the primary endpoint (overall vaccine efficacy) was assessed in the first 11 months, a

295 rther immunoinformatic analyses for enhanced vaccine efficacy, we selected the 18- most promising epi

296 In CVT, positive agreement and vaccine efficacy were calculated for TypeSeq and SPF10-L

297 vaccine regimen demonstrated only a trend in vaccine efficacy, whereas the monomeric gp120 regimen si

298 accination with a single dose of MenAfriVac, vaccine efficacy will be 52% (29-73) in children vaccina

299 th seven studies demonstrating a decrease in vaccine efficacy with increasing exposure dose.

300 signed for class switch further enhanced the vaccine efficacy with more IFN-gamma, IL-4, and CD8(+) m